Stifel Maintains Buy on Beta Bionics, Lowers Price Target to $22
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $25 to $22.
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $25 to $22.